Porcupine is a novel drug target that aims to address the issue of high unmet need in the area of fibrosis.
Porcupine is a key enzyme in the WNT signalling pathway. WNT signalling has been implicated in fibrogenesis, and therefore inhibition of WNT signalling is likely to prevent several mechanisms important for fibrotic disease progression.
Anti-inflammatory therapies have limited efficacy in the treatment of fibrosis. Several recent publications have shown that Porcupine inhibitors can be beneficial in the treatment of fibrotic indications, including renal, heart, lung and skin conditions. Our team of scientists have demonstrated efficacy in a mouse UUO model of kidney fibrosis with our novel agent. We are also exploring activity of a Porcupine inhibitor in models of IPF and NASH/ liver fibrosis.
By targeting this pathway, we aim to prevent progression or reverse fibrosis in patients with these devastating diseases.